Merck and Eisai Provide Update on Phase 3 LEAP-012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma ...

Adding the antiangiogenic drug to standard care does not extend overall survival among patients with metastatic esophageal ...

Allogene Therapeutics, Inc. downgraded to Hold after ALPHA3 trial setbacks. Review updated pipeline prospects and risks.

CT scan of chest, abdomen, and pelvis shows high-disease burden, including multiple mediastinal and hilar nodes, deposits in ...

Vague symptoms. Crazy blood pressure. Fruitless ER visits. Then suddenly, this doctor had stage IV cancer. Or maybe not. Her ...

First-line treatment with disitamab vedotin and toripalimab improved outcomes over chemotherapy in patients with HER2-expressing, locally advanced or metastatic urothelial carcinoma.

The City of Ada Police Department is deeply saddened to announce the passing of Police K9 Havoc, who was recently diagnosed with an aggressive form of cancer.

Renal cell carcinoma (RCC) comprises a heterogeneous group of neoplasms with variable prognoses. Chromophobe RCC, a relatively uncommon subtype, generally follows an indolent clinical course but may ...

Announced positive data from the ongoing Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line ...

As of Thursday, November 06, Iovance Biotherapeutics, Inc.’s IOVA share price has surged by 28.03%, which has investors questioning if this is right time to sell.